Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation30 Jan 2008
98,020 Orion A-shares converted into B-shares28 Jan 2008
Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease24 Jan 2008
Orion Corporation publishes 2007 Financial Statement release on 7 Feb 2008 at 8.30 EET16 Jan 2008
Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States2 Jan 2008
260,000 Orion A-shares converted into B-shares17 Dec 2007
Announcement by Orion Corporation in accordance with section 10 of chapter 2 of the Finnish Securities Market Act
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
27 Nov 2007
Appointments into Orion s Executive Management Board as of 1 January 200815 Nov 2007
Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo®13 Nov 2007
171,347 Orion A-shares converted into B-shares7 Nov 2007
Orion Corporation s publication schedules for financial reporting in 200824 Oct 2007
Orion Group Interim Report 1-9/200724 Oct 2007
  • Previous
  • 1
  • More pages
  • 76
  • 77
  • 78
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130